Use of adenovirus in vaccines for HIV

Handb Exp Pharmacol. 2009;(188):275-93. doi: 10.1007/978-3-540-71029-5_13.


The best hope of controlling the HIV pandemic is the development of an effective vaccine. In addition to the stimulation of virus neutralising antibodies, a vaccine will need an effective T-cell response against the virus. Vaccines based on recombinant adenoviruses (rAd) are promising candidates to stimulate anti-HIV T-cell responses. This review discusses the different rAd vector types, problems raised by host immune responses against them and strategies that are being adopted to overcome this problem. Vaccines need to target and stimulate dendritic cells and thus the tropism and interaction of rAd-based vaccines with these cells is covered. Different rAd vaccination regimes and the need to stimulate mucosal responses are discussed together with data from animal studies on immunogenicity and virus challenge experiments. The review ends with a discussion of the recent disappointing Merck HIV vaccine trial.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Adenoviridae / genetics
  • Adenoviridae / immunology*
  • Animals
  • Clinical Trials as Topic
  • Dendritic Cells / immunology
  • Dendritic Cells / virology
  • Genetic Vectors / immunology*
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • Humans
  • Immunity, Mucosal
  • T-Lymphocytes / immunology
  • T-Lymphocytes / virology
  • Treatment Outcome
  • Vaccination / methods
  • Vaccines, Synthetic / immunology


  • AIDS Vaccines
  • Vaccines, Synthetic